Anti-CD37 antibody is currently being evaluated in adult B-cell malignancies (NHL, CLL, MM, ALL) as a drug conjugate with the maytansine derivative DM1 (20). Here, CD37 is linked to B-cell chronic lymphocytic leukemia.